Price$16.47-0.61 (-3.57%)
01:30 PM07:45 PM
News · 26 weeks57+100%
2026-04-192026-10-11
Mix2590d
- Insider11(44%)
- Other7(28%)
- SEC Filings4(16%)
- Analyst3(12%)
Latest news
25 items- ANALYSTWilliam Blair initiated coverage on ImmunomeWilliam Blair initiated coverage of Immunome with a rating of Outperform
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 120,900 shares of common stock and 7,200 restricted stock units ("RSUs") to ten new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).Each stock
- SECImmunome Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Immunome Inc. (0001472012) (Filer)
- ANALYSTStifel initiated coverage on Immunome with a new price targetStifel initiated coverage of Immunome with a rating of Hold and set a new price target of $24.00
- PRImmunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid TumorsIM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancerCompany expects to initiate Phase 1 first-in-human study in patients with advanced solid tumors in the fourth quarter of 2026IM-1340 is Immunome’s fifth program in clinical developmentImmunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potent
- ANALYSTAlliance Global Partners initiated coverage on Immunome with a new price targetAlliance Global Partners initiated coverage of Immunome with a rating of Buy and set a new price target of $32.00
- INSIDERChief Scientific Officer Higgins Jack exercised 18,000 shares at a strike of $1.35, sold $334,224 worth of shares (13,200 units at $25.32) as part of a pre-agreed trading plan and gifted 8,800 shares, decreasing direct ownership by 7% to 56,250 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on September 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 86,500 shares of common stock to four new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).Each stock option has an exercise price per
- PRImmunome to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceImmunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.About Immunome, Inc.Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in
- INSIDERDirector Barchas Isaac sold $2,198,910 worth of shares (83,464 units at $26.35) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 92,211 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- SECSEC Form S-8 filed by Immunome Inc.S-8 - Immunome Inc. (0001472012) (Filer)
- SECSEC Form 10-Q filed by Immunome Inc.10-Q - Immunome Inc. (0001472012) (Filer)
- SECImmunome Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immunome Inc. (0001472012) (Filer)
- PRImmunome Reports Second Quarter 2026 Financial Results and Provides Business UpdateVaregacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improvements across the primary and all key secondary endpoints First patient dosed in June 2026 in Phase 1 trial of IM-1617, a potential first-in-class solid tumor antibody-drug conjugate incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload First patient dosed in July 2026 in Phase 1 trial of IM-3050, an investigational fibroblast activation prote
- INSIDERDirector Barchas Isaac sold $940,453 worth of shares (36,088 units at $26.06) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERCHIEF BUSINESS OFFICER Horn Kinney exercised 90,616 shares at a strike of $11.89 and sold $2,273,555 worth of shares (90,616 units at $25.09) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 176,500 shares of common stock to nine new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to
- INSIDERChief Scientific Officer Higgins Jack was granted 38,250 shares, increasing direct ownership by 174% to 60,250 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Technical Officer Tsai Philip was granted 38,250 shares, increasing direct ownership by 88% to 81,550 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERCHIEF LEGAL OFFICER & GC Stoneman Sandra G. was granted 38,250 shares, increasing direct ownership by 689% to 43,805 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERCHIEF BUSINESS OFFICER Horn Kinney was granted 31,250 shares (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Financial Officer Rosett Max was granted 47,250 shares, increasing direct ownership by 87% to 101,287 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERPresident and CEO Siegall Clay B was granted 180,000 shares, increasing direct ownership by 26% to 870,704 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Medical Officer Lechleider Robert was granted 54,000 shares, increasing direct ownership by 342% to 69,805 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid TumorsIM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells.The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-expressing advanced solid tumors.Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing a
IMNM FAQ
7 questionsWhat does Immunome Inc. do?
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.Where does IMNM stock trade?
Immunome Inc. (IMNM) is listed on NASDAQ.What sector and industry is IMNM in?
Immunome Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immunome Inc. go public?
Immunome Inc. (IMNM) completed its IPO in 2020.What are analysts saying about IMNM?
Immunome Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-10-16. Recent price targets range from $2400.00 to $4000.00.What companies are similar to IMNM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMNM side-by-side with any of them on Quantisnow.How can I track IMNM on Quantisnow?
Quantisnow aggregates Immunome Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMNM to receive live email and push alerts on every new disclosure.